The World Health Organization reports that health authorities in the Democratic Republic of the Congo have confirmed a fresh Ebola Virus Disease (EVD) outbreak in Mbandaka Health Zone, Équateur Province in the north-western part of the country. This event comes at a time when the 42-day countdown to the end of the EVD outbreak in Ituri, North Kivu and South Kivu Provinces was relaunched following re-emergence of the outbreak in Beni. As of 1 June 2020, a total of six EVD cases, including three confirmed and three probable cases have been reported.
The European Union approved a new vaccine to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged 1 year and older. The vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster.
The Democratic Republic of Congo has reported five new Ebola cases just as World Health Organization was preparing to declare an end to the outbreak.
According to the World Health Organization, since 17 February 2020, there have been no new cases of Ebola reported in the ongoing Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo.
There are no new cases of Ebola reported in the Democratic Republic of Congo since 17 February 2020. The World Health Organization requests $20 million to maintain surveillance and response operations until the end of the outbreak declaration. The WHO has not received new funding for the Ebola response since December 2019.
For years, researchers who studied Ebola had tried to develop vaccines and drugs to combat the virus. And for years, they had seen promising work stimied by no potential for drug makers to recoup development costs; and the sporardic nature of Ebola outbreaks provided little opportunity to subject experimental vaccines to rigorous tests.
The ability to examine how specific antibodies react with the Ebola virus has led to the development of a drug with far higher survival rates.
An Ebola survivor fell ill with the disease for a second time in eastern Congo, the Congolese health authorities said it was not yet clear if it was a case of relapse or reinfection.
Investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).
Researchers presented a novel method for risk assessment based on a two-layer temporal network. The method has the ability to assess the risk of Ebola virus disease spreading. Simulation results from the two-layer temporal network confirmed that reduced physical contact with people while travelling along with other preventive measures decreases the risk of Ebola spreading.